600 results on '"Guttman-Yassky, Emma"'
Search Results
2. Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies
3. Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo
4. Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
5. Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
6. A Review of Atomic-Force Microscopy in Skin Barrier Function Assessment
7. Beyond Avoidance: Advanced Therapies for Contact Dermatitis
8. A clinician’s guide to pediatric and adolescent alopecia areata treatments
9. Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations
10. Regulatory T-cell dysfunction and cutaneous exposure to Staphylococcus aureus underlie eczema in DOCK8 deficiency
11. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
12. Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa
13. Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines
14. Diversity of atopic dermatitis and selection of immune targets
15. Melanoma clinicopathological groups characterized and compared with dermoscopy and reflectance confocal microscopy
16. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo
17. Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI
18. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata
19. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults
20. The role of Janus kinase signaling in the pathology of atopic dermatitis
21. Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis
22. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis
23. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort
24. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin
25. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
26. Atopic Dermatitis Yardstick update
27. Oral Janus kinase inhibitors for atopic dermatitis
28. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
29. Repurposing DPP4 Inhibition to Improve Hair Follicle Activation and Regeneration
30. Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
31. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
32. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
33. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study
34. Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures
35. Obesity alters pathology and treatment response in inflammatory disease
36. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis.
37. Evolution of pathologic B‐cell subsets and serum environment‐specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood.
38. Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling.
39. Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses.
40. Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials.
41. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
42. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
43. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets
44. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients
45. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
46. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
47. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
48. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study
49. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients
50. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.